GlobeNewsWire
18 Aug 2026, 15:19 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Cellution Biologics has completed the acquisition of the SimpliDerm business from Elutia Inc. for an initial $8 million payment. — The acquisition represents a direct cash inflow for Elutia (Nasdaq: ELUT) and a strategic expansion for Cellution.
+0.40The acquisition marks Cellution Biologics' official entry into the U.S. reconstructive surgery market. — Entering a new surgical category diversifies the company's revenue streams and expands its addressable market.
+0.30Cellution Biologics may pay up to an additional $3 million in transition and commercial milestone payments over the next 18 months. — This creates contingent future liabilities for Cellution and potential additional upside for Elutia based on performance.
+0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
The company successfully completed the sale of its SimpliDerm business for up to $11 million.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
57m ago
